Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
RNXTthis companyRenovoRx, Inc.	$1.26	-2.63×	5.47×	26.43×	-2.05×	-30.1%	70.9%	-1114.0%	-994.5%	-206.0%	-200.5%	-37.0%	0.04×	0.61×	0×	4.02×	0.0%	3	2.98	2	C+
ANVSAnnovis Bio, Inc.	$0.88	-2.47×	4.22×	0×	-1.79×	-22.9%	0.0%	0.0%	0.0%	-171.2%	-170.2%	-36.0%	0×	0.68×	0×	5.8×	0.0%	1	-18.04	2	C+
CALCCalciMedica, Inc.	$1.43	-3.35×	-14,896.04×	0×	-3,521.14×	-100.0%	0.0%	0.0%	0.0%	445.1%	-209.1%	-0.0%	-1.46×	0.06×	-16.26×	3.58×	0.0%	3	-15.99	1	C-
CELUCelularity Inc.	$0.76	-0.31×	-0.75×	1.07×	-0.81×	-1859.9%	24.4%	-230.9%	-345.4%	241.0%	-151.1%	-46.6%	-1.07×	-0.45×	-9.08×	0.15×	20.8%	3	-16.24	2	C
ELUTElutia Inc	$0.77	0.54×	1.04×	2.33×	-0.26×	-90.4%	53.7%	-149.8%	434.2%	192.9%	-43.9%	-162.7%	0.4×	1.87×	47.58×	2.22×	0.0%	5	-6.59	3	B+
LTRNLantern Pharma Inc.	$0.57	-1.93×	5.05×	0×	-6.26×	-1222.3%	0.0%	0.0%	0.0%	-262.0%	-21.1%	-47.5%	12.02×	-4.33×	0×	2.4×	0.0%	1	-22.94	2	C+
Peer median	—	-1.93×	1.04×	0×	-1.79×	-100.0%	0.0%	0.0%	0.0%	192.9%	-151.1%	-46.6%	0×	0.06×	0×	2.4×	0.0%	3	-16.24	2	—